,
Department of General Medicine, "Hospital de Getafe”, Madrid, Spain
Division of Orthopaedics and Trauma Surgery, “Complejo Hospitalario Universitario de Toledo", Toledo, Spain
Division of Anaesthesia, Analgesia and Intensive Care and Pain Therapy, Department of Emergency and Major Trauma, "Ospedali Riuniti di Ancona", Ancona, Italy
Division of Anaesthesia, Analgesia and Intensive Care and Pain Therapy, Department of Emergency and Major Trauma, "Ospedali Riuniti di Ancona", Ancona, Italy
Orthopaedics and Traumatology Unit, Department of Surgical and Biomedical Science, S.M. Misericordia Hospital, University of Perugia, Sant'Andrea delle Fratte, Perugia, Italy
Aim
Facial aesthetics is at present a concept intricately linked to the degree of self-esteem. Unwanted submental fat (SMF) leads to an unattractive submental profile. Sodium deoxicolate (ATX) -101 is the only injectable drug approved to decrease submental fat of moderate to severe intensity.
Methods
We carried out a bibliographic review in PubMed using the key words: deoxycholic acid, ATX-101, and submental fat.
Only complete articles published between 2009 and 2019, and focused on submental fat were reviewed, excluding those articles relating to that spoke of deoxycholate in the treatment of fat in other locations or in which deoxycholate was associated with other drugs.
Results
In several phase III clinical trials, injection of 2 mg/cm2 deoxycholic acid in SMF has reduced moderate-severe fullness compared to the placebo group. These results were maintained in most cases during a long follow-up period. Injections of
deoxycholic acid are generally well tolerated, with limited adverse effects in the treatment area, with a mild and complete resolution without sequelae. However, not all patients with SMF are suitable for deoxycholic acid therapy, and therefore a proper selection is very important to achieve the desired aesthetic results.
Conclusion
Deoxycholic acid injections are effective and are a generally well-tolerated, minimally invasive option for the treatment
of moderate to severe intensity SMF in selected adults.
Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. 
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.